$HQY

Fiore Michael Henry sold $235K of HQY

Fiore Michael Henry (EVP, CHIEF COMMERCIAL OFFICER) sold 2,470 shares of HEALTHEQUITY, INC. (HQY) at $95.00 ($0.23M total) on 2026-07-02 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Fiore Michael Henry
Published Jul 7, 2026, 8:36 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 7, 2026, 8:37 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$HQY
Neutral
high confidence
Mentioned
$HQY
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$HQYNeutralLow
01

Why it matters

The disclosed open-market sale is pre-arranged under a Rule 10b5-1 plan, reducing the likelihood of a strong negative read-through versus discretionary selling.

02

Market read

Traders may note the insider sale for sentiment, but there is no new operational or financial information to drive repricing.

03

What to watch

The filing does not state motives beyond the 10b5-1 plan; without concurrent fundamentals (guidance, contracts, litigation), the trading signal is likely sentiment-only.

Relevance 3/10Novelty 3/10Timing: Filed July 7, 2026 (covers sale dated July 2, 2026).

Background

The article is an SEC Form 4 insider transaction disclosure for HEALTHEQUITY, INC. (HQY).

Company-level read

Ticker impact

$HQYNeutralHigh confidence
Context

SEC Form 4 shows HQY EVP/Chief Commercial Officer Fiore Michael Henry sold 2,470 shares at $95 on a 10b5-1 plan.

Expected impact

Low near-term impact; any reaction is likely muted given the pre-arranged 10b5-1 structure.

Evidence & confidence

The filing is a disclosed open-market sale under a pre-arranged 10b5-1 plan, with no accompanying earnings, guidance, or operational change.

Market effects

Minimal; this is company-specific insider transaction with no sector-wide regulatory or operational trigger.

None indicated.

None indicated.

Counterpoint

Even with 10b5-1, repeated insider selling can coincide with internal caution; traders may still watch for follow-on sales or changes in buying activity.

Key entities

  • HEALTHEQUITY, INC.

    Subject of the Form 4 insider transaction; EVP/Chief Commercial Officer sold shares under a 10b5-1 plan.

  • Fiore Michael Henry

    EVP, Chief Commercial Officer; reported open-market sale of 2,470 shares at $95.

Related articles

$HQYMed

HealthEquity rating upgraded by Moody’s on strong cash flow

Moody’s upgraded HealthEquity, Inc. (NASDAQ:HQY) corporate family rating to Ba2 from Ba3 and raised its probability of default rating to Ba2-PD from Ba3-PD. It also upgraded $600 million senior unsecured notes to Ba3 from B1, with outlook changed to stable. Moody’s cited stronger operating cash flow and BenefitWallet integration, plus improved leverage and liquidity.

$HQYMedAI 9/10

HealthEquity Q1 2027 Earnings Call: Complete Transcript - HealthEquity (NASDAQ: HQY)

HealthEquity reported fiscal 2027 first-quarter results, citing 7% year-over-year revenue growth and a record adjusted EBITDA margin of 46%, according to the company. It raised guidance to $1.41–$1.42B revenue and $625–$633M adjusted EBITDA. The firm said it expanded digital engagement and Marketplace, used AI for efficiency, saw HSA assets +19% and new HSA sales +15%, and increased its share repurchase authorization by $1B.